Medifast Announces First Quarter 2024 Financial Results

Rhea-AI Summary

Medifast reported first quarter 2024 financial results with revenue of $174.7 million, net income of $8.3 million, and EPS of $0.76. The company highlighted a transformative approach to weight loss solutions, targeting a potential $50B market. However, revenue decreased by 49.9% primarily due to lower Coach productivity and active earning OPTAVIA Coaches. Gross profit decreased by 48.3%, while selling, general, and administrative expenses decreased by 38.1%. Income from operations decreased by 85.2% to $7.9 million. The company's balance sheet remained strong with $156.4 million in cash and no debt. The outlook for the second quarter 2024 includes revenue between $150 million to $170 million and diluted EPS between $0.05 to $0.40.

Positive

• None.

Negative

• First quarter 2024 revenue decreased by 49.9% to $174.7 million compared to the first quarter of 2023, attributed to lower Coach productivity and active earning OPTAVIA Coaches.

• Gross profit decreased by 48.3% to $127.3 million due to lower revenue, despite some efficiencies in inventory management and cost savings.

• Selling, general, and administrative expenses decreased by 38.1% to $119.4 million, but as a percentage of revenue, SG&A increased to 68.3% due to market research and investment costs.

• Income from operations decreased by 85.2% to $7.9 million, with a percentage of revenue at 4.5% compared to 15.3% in the prior year period.

Insights

Financial Analyst

Medifast's first quarter report indicates a significant revenue decrease of 49.9% compared to the prior year, attributed mainly to a reduction in active earning OPTAVIA Coaches and lower productivity. This contraction signals potential issues in customer acquisition and retention. The reported increase in gross profit margin from 70.6% to 72.8% reflects cost efficiencies; however, the rise in SG&A as a percentage of revenue from 55.3% to 68.3% could indicate rising operational costs not sufficiently offset by revenues. Investors should note the sharp decline in net income from $40.0 million to $8.3 million and the corresponding decline in EPS from $3.67 to $0.76 year-over-year, a key metric for evaluating company profitability and performance. Medifast's strong balance sheet with $156.4 million in cash and no debt provides some cushion against short-term volatility. The forward-looking statements regarding the second quarter's revenue and EPS forecast represent a cautious approach, with a wide EPS range of $0.05 to $0.40, reflecting uncertainty and potential volatility.

Market Research Analyst

The emphasis on transitioning towards medically supported weight loss solutions highlights Medifast's strategic pivot to address a growing market, estimated to potentially reach $50 billion by 2030. While Medifast's new company-led national marketing campaign aims to enhance brand visibility and awareness, the increased investment raises concerns over whether the benefits will outweigh the costs, especially following a decline in active earning coaches and revenue. The emphasis on differentiating their offer through comprehensive support, including habit-based coaching, suggests a shift in competitive strategy to capture more of the market. This move, however, comes with the inherent risk of executing a shift in business model under uncertain market conditions. The retail investor should monitor how these strategic investments play out in the medium to long term against the backdrop of current financial performance concerns.

BALTIMORE--(BUSINESS WIRE)-- Medifast (NYSE: MED), the health and wellness company known for its habit-based and Coach-guided lifestyle solution, OPTAVIA®, today reported results for the first quarter ended March 31, 2024.

First Quarter 2024

• Revenue of $174.7 million, with revenue per active earning coach of $4,623
• Independent active earning OPTAVIA Coaches of 37,800
• Net income of $8.3 million (non-GAAP adjusted net income of $7.2 million)
• Earnings per diluted share ("EPS") of $0.76 (non-GAAP adjusted EPS of $0.66)
• Cash, Cash Equivalents, and Investment Securities of $156.4 million with zero debt

“Fast paced medical innovation is providing greater access to medical weight loss solutions than ever before. We are transforming our OPTAVIA offer to include comprehensive support for consumers who wish to use GLP-1 medical weight loss solutions on their individual journeys to sustainable healthy lifestyles. It’s a market that is estimated by a recent BCG market study to have the potential to grow to $50B or more by 2030, and it’s one that we are uniquely positioned to capitalize on,” said Dan Chard, Chairman & Chief Executive Officer.

“Our new model is highly differentiated from competitors, with a holistic approach including our habit-based and Coach guided solution along with nutrition products and community support. It will be supported by a reimagined framework for customer acquisition, with a new company-led national marketing campaign, enhancing both awareness of the benefits of our approach, and the visibility of our brand. While 2024 will be a year of investment for future growth, we believe the initiatives we are undertaking will be foundational in creating a platform for sustained company growth in the years ahead.”

First Quarter 2024 Results

First quarter 2024 revenue decreased 49.9% to $174.7 million from $349.0 million for the first quarter of 2023, primarily driven by a decrease in the number of active earning OPTAVIA Coaches, lower Coach productivity, and a $9.1 million impact from a timing difference related to changes in the company’s sales order terms and conditions with its customers realized in the first quarter of 2023. The total number of active earning OPTAVIA Coaches decreased 35.6% to 37,800 compared to 58,700 for the first quarter of 2023. The average revenue per active earning OPTAVIA Coach was $4,623, compared to $5,945 for the first quarter last year, primarily driven by continued pressure on customer acquisition.

Gross profit decreased 48.3% to $127.3 million from $246.4 million for the first quarter of 2023. The decrease in gross profit was due to lower revenue, partially offset by efficiencies in inventory management and cost savings from Fuel for the Future initiatives. Gross profit margin was 72.8% compared to 70.6% in the first quarter of 2023, primarily due to efficiencies in inventory management and cost savings from Fuel for the Future initiatives, partially offset by increased shipping costs.

Selling, general, and administrative expenses (“SG&A”) decreased 38.1% to $119.4 million compared to $192.9 million for the first quarter of 2023. The decrease in SG&A was primarily due to lower OPTAVIA Coach compensation expense due to lower volumes and fewer active earning Coaches, partially offset by market research and investment costs related to medically supported weight loss activities and costs for company-led acquisition initiatives. As a percentage of revenue, SG&A increased 1,300 basis points year-over-year to 68.3% of revenue, as compared to 55.3% for the first quarter of 2023. The increase in SG&A as a percentage of revenue was primarily due to market research and investment costs related to medically supported weight loss activities, loss of leverage on fixed costs due to lower sales volumes, and costs for company-led acquisition initiatives. Non-GAAP adjusted SG&A, which excludes expenses to initiate and operationalize the LifeMD, Inc. (“LifeMD”) collaboration, decreased 38.8% to $118.0 million and non-GAAP adjusted SG&A as a percentage of revenue increased 1,220 basis points year-over-year to 67.5%.

Income from operations decreased 85.2% to $7.9 million from $53.5 million in the prior year period. As a percentage of revenue, income from operations was 4.5% for the first quarter of 2024 compared to 15.3% in the prior-year period. Non-GAAP adjusted income from operations decreased 82.7% to $9.3 million. Non-GAAP adjusted income from operations as a percentage of revenue was 5.3%, a decrease of 1,000 basis points from the year-ago period.

The effective tax rate was 28.2% for the first quarter of 2024 compared to 25.1% in the prior-year period. The increase in the effective tax rate from the three months ended March 31, 2023 was primarily driven by an increase in the tax shortfall for stock compensation and the rate impact of research and development tax credits, partially offset by the decrease in the limitation for executive compensation and various other miscellaneous items. The non-GAAP effective tax rate was 28.7% as compared to 25.1% in the prior year period.

In the first quarter of 2024, net income was $8.3 million, or $0.76 per diluted share, based on approximately 11.0 million shares of common stock outstanding. In the first quarter of 2023, net income was $40.0 million, or $3.67 per diluted share, based on approximately 10.9 million shares of common stock outstanding. In the first quarter 2024, non-GAAP adjusted net income was $7.2 million, or $0.66 per diluted share.

Capital Allocation and Balance Sheet

The company’s balance sheet remains strong with $156.4 million in cash, cash equivalents and investment securities and no interest-bearing debt as of March 31, 2024 compared to $150.0 million in cash, cash equivalents and investment securities and no debt at December 31, 2023.

Outlook

The company expects second quarter 2024 revenue to be in the range of $150 million to $170 million and second quarter 2024 diluted EPS to be in the range of $0.05 to $0.40. The EPS range excludes the costs related to the initiation of the LifeMD collaboration and any gains or losses from changes in the market price of the company’s LifeMD common stock investment.

Conference Call Information

The conference call is scheduled for today, Monday, April 29, 2024 at 4:30 p.m. ET. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast’s website at www.MedifastInc.com or directly at https://viavid.webcasts.com/starthere.jsp?ei=1663236&tp_key=1b6e0e1efe and will be archived online and available through July 29, 2024. In addition, listeners may dial (877) 451-6152 to join via telephone. A telephonic playback will be available from 8:30 p.m. ET, April 29 2024, through May 6, 2024. Participants can dial (844) 512-2921 and enter passcode 13745406 to hear the playback.

About Medifast^®:

Medifast (NYSE: MED) is the health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA®, which provides people with a simple, yet comprehensive approach to help them achieve lasting optimal health and wellbeing. OPTAVIA's lifestyle plans deliver clinically proven health benefits as well as evidence-based tools, including scientifically developed products and a framework for habit creation reinforced by independent Coaches and Community support. As a physician-founded company with a 40+ year history, Medifast is a leader in the U.S. weight management industry. Through a collaboration with the national virtual primary care provider LifeMD, OPTAVIA customers have access to board-certified affiliated clinicians and medications, such as GLP-1s, that support treatment plans for obesity and other health conditions. The company continues to innovate and build upon its scientific and clinical heritage to fulfill its mission of offering the world Lifelong Transformation, One Healthy Habit at a Time®. Medifast was recognized in 2023 by Financial Times as one of The Americas' Fastest Growing Companies and in 2022 as one of America’s Best Mid-Sized Companies by Forbes. For more information, visit MedifastInc.com and OPTAVIA.com and follow @Medifast on X.

MED-F

Forward Looking Statements

Please Note: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend," "anticipate," "expect" or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals, outlook or targets contained herein are also considered forward-looking statements. These statements are based on the current expectations of the management of Medifast and are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Medifast's inability to maintain and grow the network of independent OPTAVIA Coaches; Industry competition and new weight loss products, including weight loss medications, or services; Medifast’s health or advertising related claims by our OPTAVIA customers; Medifast's inability to continue to develop new products; effectiveness of Medifast's advertising and marketing programs, including use of social media by OPTAVIA Coaches; the departure of one or more key personnel; Medifast's inability to protect against online security risks and cyberattacks; risks associated with Medifast's direct-to-consumer business model; disruptions in Medifast's supply chain; product liability claims; Medifast's planned growth into domestic markets including through its collaboration with LifeMD, Inc.; adverse publicity associated with Medifast's products; the impact of existing and future laws and regulations on Medifast’s business; fluctuations of Medifast's common stock market price; increases in litigation; actions of activist investors; the consequences of other geopolitical events, overall economic and market conditions and the resulting impact on consumer sentiment and spending patterns; and Medifast's ability to prevent or detect a failure of internal control over financial reporting. Although Medifast believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and other filings filed with the United States Securities and Exchange Commission, including its quarterly reports on Form 10-Q and current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

 

MEDIFAST, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(U.S. dollars in thousands, except per share amounts & dividend data)
	Three Months Ended March 31,
		2024			2023
Revenue	$	174,739		$	348,983
Cost of sales		47,447			102,593
Gross profit		127,292			246,390
Selling, general, and administrative		119,352			192,879
Income from operations		7,940			53,511
Other income (expense)
Interest income (expense)		1,223			(181	)
Other income (expense)		2,422			(1	)
		3,645			(182	)
Income from operations before income taxes		11,585			53,329
Provision for income taxes		3,269			13,361
Net income	$	8,316		$	39,968
Earnings per share - basic	$	0.76		$	3.68
Earnings per share - diluted	$	0.76		$	3.67
Weighted average shares outstanding
Basic		10,909			10,864
Diluted		10,958			10,899
Cash dividends declared per share	$	—		$	1.65

 

MEDIFAST, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (U.S. dollars in thousands, except par value)
	March 31, 2024			December 31, 2023
ASSETS
Current Assets
Cash and cash equivalents	$	97,471		$	94,440
Inventories		46,273			54,591
Investments		58,957			55,601
Income taxes, prepaid		5,471			8,727
Prepaid expenses and other current assets		11,412			10,670
Total current assets		219,584			224,029
Property, plant and equipment - net of accumulated depreciation		50,986			51,467
Right-of-use assets		14,536			15,645
Other assets		13,648			14,650
Deferred tax assets		4,005			4,117
TOTAL ASSETS	$	302,759		$	309,908
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable and accrued expenses	$	71,229		$	86,415
Current lease obligations		5,958			5,885
Total current liabilities		77,187			92,300
Lease obligations, net of current lease obligations		14,611			16,127
Total liabilities		91,798			108,427
Stockholders' Equity
Common stock, par value $0.001 per share: 20,000 shares authorized;
10,937 and 10,896 issued and outstanding
at March 31, 2024 and December 31, 2023, respectively		11			11
Additional paid-in capital		27,963			26,573
Accumulated other comprehensive income		22			248
Retained earnings		182,965			174,649
Total stockholders' equity		210,961			201,481
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	302,759		$	309,908

Non-GAAP Financial Measures

In an effort to provide investors with additional information regarding the company's results, the company discloses various non-GAAP financial measures in its quarterly earnings press release and other public disclosures. The following GAAP financial measures have been presented on an as adjusted basis: SG&A expenses, income from operations, other income (expense), provision for income taxes, net income and diluted EPS. Each of these non-GAAP financial measures excludes the impact of certain amounts to initiate and operationalize the LifeMD collaboration and unrealized gains on investment in LifeMD common stock as further identified below and have not been calculated in accordance with GAAP. A reconciliation of each of these non-GAAP financial measures to its most comparable GAAP financial measure is included below. These non-GAAP financial measures are not intended to replace GAAP financial measures.

The company uses these non-GAAP financial measures internally to evaluate and manage the company's operations because it believes they provide useful supplemental information regarding the company's on-going economic performance. The company has chosen to provide this information to investors to enable them to perform more meaningful comparisons of operating results and as a means to emphasize the results of on-going operations.

The following tables reconcile the non-GAAP financial measures included in this release:

 

MEDIFAST, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED NON-GAAP (UNAUDITED)
(U.S. dollars in thousands, except per share amounts)
	Three months ended March 31, 2024
	GAAP				Unrealized Gain on Investment in LifeMD Common Stock			LifeMD Prepaid Services Amortization				Non-GAAP
Selling, general, and administrative	$	119,352			$	—		$	(1,327	)		$	118,025
Income from operations		7,940				—			1,327				9,267
Other income (expense)		3,645				(2,841	)		—				804
Provision for income taxes		3,269				(710	)		332				2,891
Net income		8,316				(2,130	)		995				7,181
Diluted earnings per share (1)		0.76				(0.19	)		0.09				0.66
	Three Months Ended March 31, 2023
	GAAP				Unrealized Gain on Investment in LifeMD Common Stock			LifeMD Prepaid Services Amortization				Non-GAAP
Selling, general, and administrative	$	192,879			$	—		$	—			$	192,879
Income from operations		53,511				—			—				53,511
Other income (expense)		(182	)			—			—				(182	)
Provision for income taxes		13,361				—			—				13,361
Net income		39,968				—			—				39,968
Diluted earnings per share (1)		3.67				—			—				3.67

(1)

The weighted-average diluted shares outstanding used in the calculation of these non-GAAP financial measures are the same as the weighted-average shares outstanding used in the calculation of the reported per share amounts.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240429772740/en/

Investor Contact:

Medifast, Inc.

Steven Zenker

InvestorRelations@medifastinc.com

(443) 379-5256

Source: Medifast, Inc.

FAQ

What was Medifast's revenue for the first quarter of 2024?

Medifast reported revenue of $174.7 million for the first quarter of 2024.

What was the net income for Medifast in the first quarter of 2024?

Medifast's net income was $8.3 million for the first quarter of 2024.

How many active earning OPTAVIA Coaches did Medifast have in the first quarter of 2024?

Medifast had 37,800 active earning OPTAVIA Coaches in the first quarter of 2024.

What was the EPS for Medifast in the first quarter of 2024?

Medifast reported earnings per diluted share (EPS) of $0.76 for the first quarter of 2024.

What is Medifast's cash position as of March 31, 2024?

As of March 31, 2024, Medifast had $156.4 million in cash, cash equivalents, and investment securities with zero debt.